USE OF GNRH ANTAGONISTS VS AGONISTS PROTOCOL FOR IVF/ICSI IN THE REAL WORLD - EXPERIENCE OF OVER 11,000 CYCLES

被引：0
|
作者：
Bosch, E. [1 ]
Crespi, S. [2 ]
Garrido, N. [1 ]
Meseguer, M. [1 ]
Hu, H. [2 ]
机构：
[1] IVI Valencia, Valencia, Spain
[2] Merck & Co Inc, Whitehouse Stn, NJ USA
来源：
FERTILITY AND STERILITY | 2012年 / 98卷 / 03期
关键词：
D O I：
10.1016/j.fertnstert.2012.07.638
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
P-210
引用
收藏
页码：S173 / S173
页数：1
相关论文
共 9 条
  • [1] GNRH agonists versus antagonists: outcome of over 4000 ICSI cycles
    Tavmergen, E.
    Sahin, G.
    Akdogan, A.
    Levi, R.
    Goker, E. N. T.
    HUMAN REPRODUCTION, 2012, 27
  • [2] EVALUATION OF THE OOCYTE MORPHOLOGY IN THE PATIENTS UNDERGOING IVF-ICSI CYCLES RECEIVING GnRH AGONISTS AND ANTAGONISTS PROTOCOLS: A RETROSPECTIVE STUDY.
    Tufekci, M. A.
    Temel, S. G.
    Aybar, F.
    Yelke, H. K.
    Kahraman, S.
    FERTILITY AND STERILITY, 2013, 100 (03) : S228 - S228
  • [3] Use of steroid pre-treatments in IVF-ICSI cycles with GnRH antagonist protocol and their impact on gestational outcomes
    Fernandez-Prada, Sara
    Martin-Camean, Maria
    Armijo, Onica
    Diez-Sebastian, Jesus
    Iniesta, Silvia
    Lobo, Sonia
    Silva, Patricia
    Sanz, Clara
    Jose Sanchez, Maria
    Hernandez, Alicia
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2022, 42 (03) : 478 - 484
  • [4] Reproductive performance in second IVF cycles treated with the use of either GnRH anatgonists (-antag) vs GnRH agonists (-ag) after failure with long protocols with GnRH agonists: a prospective randomized trial
    Inza, R
    Van Thillo, G
    Lombardi, E
    Bisioli, C
    Diradourian, M
    Kenny, A
    FERTILITY AND STERILITY, 2004, 82 : S233 - S234
  • [5] Stimulation mit GnRH-Antagonisten bei IVF/ICSI Verbesserung der „Therapieerfahrung“: Vorschlag eines Stimulationsprotokolls unter Begleitmedikation mit GnRH-Antagonisten Stimulation with GnRH antagonists for IVF/ICSIImprovement of “therapy experience”: proposal for a stimulation protocol and co-treatment with GnRH antagonists
    R. Felberbaum
    Der Gynäkologe, 2009, 42 (8): : 636 - 638
  • [6] Real-world insights into risk of developing cardiovascular disease following GnRH agonists versus antagonists for prostate cancer: a methodological protocol to a study using five European databases
    George, Gincy
    Scailteux, Lucie-Marie
    Garmo, Hans
    Balusson, Frederic
    Cardwell, Christopher
    De Coster, Greet
    De Schutter, Harlinde
    Kuiper, Josephina G.
    McMenamin, Una
    Verbeeck, Julie
    Van Hemelrijck, Mieke
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2019, 33 (04) : 479 - 499
  • [7] Controlled ovarian stimulation (COH) in IVF cycles involving women over the age of 40 years: Comparing outcomes between protocols using LH add-back vs. r-FSH alone in cycles utilizing GnRH antagonists.
    Thornton, K.
    Ryley, D.
    Alper, M. M.
    Ezcurra, D.
    FERTILITY AND STERILITY, 2006, 86 : S141 - S142
  • [8] High initial FSH dosage reduces the number of available cleavage-stage embryos in a GnRH-antagonist protocol: Real-world data of 8,772 IVF cycles from China
    Luo, Xiu
    Pei, Li
    He, Yao
    Li, Fujie
    Han, Wei
    Xiong, Shun
    Han, Shubiao
    Li, Jingyu
    Zhang, Xiaodong
    Huang, Guoning
    Ye, Hong
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [9] EVALUATING CHANGE IN GONADOTROPIN-RELEASING HORMONE ANALOG (GNRH) USE IN A US REAL-WORLD DATABASE STUDY OF 96,446 IN VITRO FERTILIZATION CYCLES OVER 6.5 YEARS.
    Mottla, G. L.
    Richter, K. S.
    Kaplan, B.
    Hayward, B.
    Mahony, M. C.
    FERTILITY AND STERILITY, 2016, 106 (03) : E343 - E344
1